Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to demonstrate, in renal transplant patients receiving everolimus and cyclosporin, the non-inferiority of one of the two following regimens: once-a-day regimen (Group A) OR steroid withdrawal regimen (Group B) in comparison with the standard twice-a-day regimen (Group C), using the treatment failure rate (composite endpoint of biopsy-proven acute rejection, graft loss, death or lost to follow-up) between randomization and Month 12 as primary endpoint.
Critère d'inclusion
- Recipients of a de novo kidney transplant